ClinicalTrials.gg
CompletedNCT04678882Updated Sep 12, 2025

Dupilumab in Japanese Patients With Atopic Dermatitis

A Phase 3 interventional study of Placebo and Dupilumab SAR231893 in Atopic Dermatitis, sponsored by Sanofi. Completed at 19 sites in Japan. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
27th of 50
62 · median 75
Started
2021
with 4 others
Phase 3
11 of 50
none open now
Registered
30th of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 27th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 3, and was the 30th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS)

Secondary Objective:

To evaluate the efficacy of dupilumab administered concomitantly with TCS. To assess the safety of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in participants.

To assess immunogenicity as determined by the incidence, titer, and clinical impact of treatment-emergent anti-drug antibodies (ADA) to dupilumab over time in pediatric patients with atopic dermatitis (AD) (aged ≥6 months to \<18 years old) To assess the concentration of dupilumab in serum following administration concomitantly with TCS.

Read the detailed description

For participant who declines to enter open-lebal extension (OLE), the duration of the study for each participant is approximately 33 weeks (including screening and follow-up) For participant choosing enter OLE, the duration is approximately 21 weeks (including screening) plus 3 years OLE period or until approval of the indication in Japan whichever is sooner.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Japanese and ≥6 months to \<18 years of age, at the time of signing the and/or assent.

Diagnosis of AD according to the American Academy of Dermatology consensus criteria at screening visit.

Chronic AD diagnosed at least 1 year prior to the screening visit (for participants between 6 months to \<1 year of age, the requirement is to have had chronic AD for 3 months).

(Investigator's Global Assessment) IGA ≥ 3 at screening and baseline visits. (Eczema Area and Severity Index) EASI ≥16 at screening and baseline visits. Baseline peak pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity ≥4 for participants ≥12 to \<18 years of age.

Baseline worst itch NRS or worst scratch/itch NRS weekly average score for maximum itch or scratch/itch intensity ≥4 for participants ≥6 months to \<12 years of age.

Body surface area (BSA) of AD involvement >10% at screening and baseline visits.

With documented recent history (within 6 months before the baseline visit) of inadequate response to topical AD medication(s).

At least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily immediately before the baseline visit.

Willing and able to comply with all clinic visits and study-related procedures. Participant, either alone or with help of parents/legal guardians (for 6 years old to less than18 years of age) or parents/caregiver or legal guardians (for 6 months to less than 6 years of age) as appropriate, must be able to understand and complete study-related questionnaires.

Body weight ≥5 kg at baseline. use by female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion criteria:

Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit or during the screening period.

Known or suspected immunodeficiency, including history of invasive opportunistic infections Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded from the study unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist.

Known history of (HIV)-1 and HIV-2 infection or HIV seropositivity at the screening

Participants with any of the following result at the screening:

  • Positive (or indeterminate) surface antigen (HBs Ag) or,
  • Positive hepatitis B core antibody (HBc Ab) confirmed by positive hepatitis B virus (HBV) DNA or,
  • Positive antibody (HCV Ab) confirmed by positive hepatitis C virus (HCV) RNA.

Presence of skin comorbidities that may interfere with study assessments History of within 5 years before the baseline visit History of systemic or anaphylaxis to dupilumab or any other biologic therapy.

Known or suspected alcohol and/or drug abuse. Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection.

Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.

Participant with any other medical or psychological condition including relevant laboratory or (ECG) abnormalities at screening Exposure to another systemic or topical investigative drug within a certain time period prior to Visit 1 (screening), Having used any of /immunomodulating drugs and phototherapy within 4 weeks before the screening visit.

Past Treatment with biologics as follows:

  • Any cell-depleting agents within 6 months before the screening visit.
  • Anti-IgE therapy within 4 months before the screening visit.
  • Other monoclonal antibodies (which are biological response modifiers): within 5 half-lives (if known) or 16 weeks before the screening visit (Visit 1), whichever is longer.

History of important side effects to medium potency TCS Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit.

Either intravenous immunoglobulin therapy and/or plasmapheresis within 30 days prior to screening visit.

Planned or anticipated use of any prohibited medications and procedures during screening and study treatment period.

Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period Participation in a prior dupilumab clinical study or have been treated with commercially available dupilumab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks

    Drug: Dupilumab SAR231893

  • Placebo comparator
    Placebo

    Double dose on day1 and followed by single dose every 2 weeks or single dose every 4 weeks

    Drug: Placebo

Interventions

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% improvement from baseline EASI)

    The EASI is a composite index with scores ranging from 0 to 72.Higher scores indicates worse condition

    Time frame: At Week 16

Secondary outcomes

  1. Percent change in EASI score

    The EASI is a composite index with scores ranging from 0 to 72.Higher scores indicates worse condition

    Time frame: From baseline to week 16

  2. Percent change in weekly average of daily worst itch numerical rating scale (NRS) for participants aged ≥6 years to <12 years old

    The worst itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old will use to report the intensity of their pruritus (itch). This is an 11-point scale (0 to 10) in which 0 indicates no itching while 10 indicate worst itching possible.

    Time frame: From baseline to week 16

  3. Proportion of participants with Investigator's Global Assessment (IGA) 0 or 1

    The IGA is an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 5-point scale ranging from 0 (clear) to 4 (severe)

    Time frame: At Week 16

  4. Percent change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old

    The peak pruritus NRS is a simple assessment tool that participants ≥ 12 to \<18 years old will use to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the' worst itch imaginable'

    Time frame: From baseline to week 16

  5. Percent change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old

    The worst scratch/itch NRS is a simple assessment tool those participants ≥6 years old to \<6 years old range from 1 to 10 in which 0 indicates no itching while 10 indicate worst itching possible

    Time frame: From baseline to week 16

  6. Percent change for intensity of pruritus

    The intensity is assessed by numerical rating scale ranging from 0 to 10 which higher scale indicate worse itch condition

    Time frame: From baseline to week 16

  7. Proportion of participants with EASI-50 (≥50% improvement from baseline)

    The EASI is a composite index with scores ranging from 0 to 72.Higher scores is worse condition

    Time frame: At Week 16

  8. Proportion of participants with EASI-90 (≥90% improvement from baseline)

    The EASI is a composite index with scores ranging from 0 to 72.Higher scores is worse condition

    Time frame: At Week 16

  9. Change in percent body surface area (BSA) affected by atopic dermatitis (AD)

    BSA affected by atopic dermatitis will be assessed for each major section of the body (head, trunk, arms, and legs).

    Time frame: From baseline to week 16

  10. Change in Children's Dermatology Life Quality Index (CDLQI) (≥4 years)

    The CDLQI is a validated questionnaire designed to measure the impact of skin disease on the Quality of Life. The higher the score, the greater the impact is on the quality of life

    Time frame: From baseline to week 16

  11. Change in Infants' Dermatitis Quality of Life Index (IDQOL) (<4 years)

    The IDQOL is a validated questionnaire developed to measure the impact of skin disease on the QOL of infants and preschool children \<4 years of age wil completed by the child's parent or caregiver. The higher the score, the greater the impact is on the quality of life. -

    Time frame: From baseline to week 16

  12. Change in Patient Oriented Eczema Measure (POEM)

    The POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire used to assess disease symptoms with a scoring system of 1 to 28. The higher score, the higher morbidity

    Time frame: From baseline to week 16

  13. Change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old

    The peak pruritus NRS is a simple assessment tool that participants ≥ 12 to \<18 years old will use to report the intensity of their pruritus (itch) ranges from 0 to 10 with 1 being 'no itch' and 10 being the' worst itch imaginable'

    Time frame: From baseline to week 16

  14. Change in weekly average of daily worst itch NRS for participants aged ≥6 years to <12 years old

    The worst itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old range from 1 to 10 in which 1 indicates no itching while 10 indicate worst itching possible -

    Time frame: From baseline to week 16

  15. Change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old

    The worst scratch/itch NRS is a simple assessment tool those participants ≥6 years old to \<12 years old range from 1 to 10 in which 1 indicates no itching while 10 indicate worst itching possible

    Time frame: From baseline to week 16

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESI) From Baseline to 16 Weeks of Treatment

    Time frame: Baseline (Day 1) to Week 16

  17. Number of Participants With Skin-Infection TEAEs (Excluding Herpetic Infections) From Baseline to 16 Weeks of Treatment

    Time frame: Baseline (Day 1) to Week 16

  18. Number of Participants With TEAEs, SAEs, and AESI From Baseline of open-label extension (OLE) Through the Last Study Visit

    Time frame: Week 16 to Week 116

  19. Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) to Dupilumab Over Time in Pediatric Participants with AD (Aged ≥6 Months to <18 Years old)

    Time frame: Baseline (Day 1) to Week 116

  20. Serum Concentration of Dupilumab up to Week 116

    Time frame: Pre-dose at Baseline (Day 1), and Weeks 4, 12, 16, 24, 32, 52, 68, 92, and 116

07

Study locations

19 sites
  • Investigational Site Number : 3920011
    Nagoya, Aichi-ken 457-8510, Japan
  • Investigational Site Number : 3920014
    Toyoake-shi, Aichi-ken 470-1192, Japan
  • Investigational Site Number : 3920015
    Fukutsu-shi, Fukuoka 811-3217, Japan
  • Investigational Site Number : 3920001
    Hiroshima, Hiroshima 734-8551, Japan
  • Investigational Site Number : 3920013
    Sapporo, Hokkaido 004-0063, Japan
  • Investigational Site Number : 3920009
    Sapporo, Hokkaido 060-0807, Japan
  • Investigational Site Number : 3920008
    Kobe, Hyōgo 653-0836, Japan
  • Investigational Site Number : 3920007
    Kobe, Hyōgo 658-0082, Japan
  • Investigational Site Number : 3920003
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Investigational Site Number : 3920017
    Yokohama, Kanagawa 221-0825, Japan
  • Investigational Site Number : 3920010
    Yokohama, Kanagawa 225-0015, Japan
  • Investigational Site Number : 3920006
    Tsu, Mie-ken 514-0125, Japan
  • Investigational Site Number : 3920020
    Sakai-shi, Osaka 593-8324, Japan
  • Investigational Site Number : 3920019
    Toyonaka-shi, Osaka 560-0085, Japan
  • Investigational Site Number : 3920016
    Kumagaya-shi, Saitama 360-0018, Japan
  • Investigational Site Number : 3920023
    Chuo-ku, Tokyo 104-0031, Japan
  • Investigational Site Number : 3920012
    Koto-ku, Tokyo 136-0074, Japan
  • Investigational Site Number : 3920022
    Toshima-ku, Tokyo 170-0002, Japan
  • Investigational Site Number : 3920021
    Habikino-shi, 583-8588, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Dec 2021, 10 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 22, 2020
StartActual
Jan 15, 2021
Primary completionActual
Dec 14, 2021
CompletionActual
Oct 28, 2023
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04678882
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Jan 15, 2021
Primary completion
Dec 14, 2021
Completion
Oct 28, 2023
Last update
Sep 12, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion